In addition, other studies have reported that BIM-I elicits anticancer activity by various mechanisms, such as halting the progression of melanoma by inhibiting the 3-phosphoinositide-dependent protein kinase-1 (PDPK1) [15,16], and impeding multi-drug resistance by either binding to P-glycoproteins [17] or inhibiting the release of exosomes and microvesicles [18]. Here, PDPK1 is linked to melanoma.